USPTO serial 97364220
FMT
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- EINSTEIN, MATTHEW T
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with FMT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
THOMAS J. SPEISS III
THOMAS J. SPEISS III Buchalter, a Professional Corporation805 S.W. Broadway, Suite 1500Portland, OR 97205UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nutraceuticals, namely, epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; nutraceuticals, namely, epigenetic drugs targeting arginine methylation in cancer; pharmaceutical preparations in the nature of inhibitors of arginine methylation for the treatment of cancer; pharmaceutical preparations in the nature of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; pharmaceutical compounds for the treatment, diagnosis, detection and prevention of cancer; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer | ABANDONED | — |
| 042 | Research and development services in the pharmaceutical and biotechnology fields; medical research and development services in the pharmaceutical and biotechnology fields; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; consultancy, advisory and information services relating to and connected with research and development in the pharmaceutical and biotechnology fields, research and development in the field of epigenetic drugs, and research and development in the field of cancer treatment, diagnosis, detection, and prevention | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 22, 2023 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Jun 22, 2023 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Jun 21, 2023 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| May 12, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 17, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 22, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 22, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 2, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 17, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 7, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 7, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 7, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 7, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 26, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 26, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 26, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 26, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 21, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 8, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 8, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 8, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 20, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 18, 2022 | NWAP | NEW APPLICATION ENTERED | — |